Loading stock data…
MSB
$23.89-0.16 (-0.67%)
Market ClosedLast close Jun 9
Mesabi Trust, a royalty trust, engages in iron ore mining business in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Mesabi Trust in the Basic Materials sector is trading at $23.89. The stock is currently near its 52-week low of $22.55, remaining 24.6% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 29) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$23.89
Potential Downside
0%
Whystock Fair Value$23.89
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Mesabi Trust, a royalty trust, engages in iron ore mining business in the United States. The company was incorporated in 1961 and is based in New York, New York.
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
4.02%
ROE
Elite ROE. Management converts capital into profit efficiently.
67.97%
Volume
Today's trading volume
55,062
Recent News
Assessing Cleveland-Cliffs (CLF) Valuation After Mesabi Trust Distribution Cut Highlights Operational Uncertainty
Mesabi Trust’s decision to cut its distribution, after receiving lower royalty payments from Cleveland-Cliffs (CLF), has drawn fresh attention to uncertainties around the miner’s Northshore iron ore operations and the related industry risks. See our latest analysis for Cleveland-Cliffs. Despite the Mesabi news, Cleveland-Cliffs' recent share price moves have been mixed, with a 1-month share price return of 12.20% and a 90-day share price return showing a 32.45% decline, while the 1-year total...
ASX April 2026 Stocks Estimated To Be Trading Below Fair Value
The Australian stock market is experiencing a period of optimism, with the ASX 200 futures seeing a significant rise as global equities receive a boost from renewed geopolitical negotiations. Amidst this fluctuating landscape, identifying stocks that are trading below their fair value can offer potential opportunities for investors looking to capitalize on market inefficiencies.
Gregory George Adds To Mesoblast Position With Multi-Market Share Purchases
Mesoblast Limited ( ASX:MSB ) shareholders (or potential shareholders) will be happy to see that insider Gregory George...
Mesoblast (ASX:MSB) Is Down 11.0% After FDA Clears Registrational DMD Trial For Ryoncil - Has The Bull Case Changed?
Mesoblast recently announced that the US FDA has granted Investigational New Drug clearance to move directly into a registrational clinical trial of Ryoncil in children with Duchenne muscular dystrophy, enrolling 76 patients aged 5 to 9 with time-to-stand at nine months as the primary endpoint. This trial positions Mesoblast to apply its first-in-class mesenchymal stromal cell therapy, already approved for pediatric steroid-refractory acute graft-versus-host disease, to a new high-need...
Is Mesoblast (ASX:MSB) Price Swings Creating A Possible Valuation Opportunity?
If you are wondering whether Mesoblast at around A$2.02 is still priced attractively or already reflecting high expectations, the valuation story matters more than ever. The share price has seen mixed returns, with a 27.1% decline year to date and a 25.9% gain over the last year, while the three year return of 112.0% contrasts with a 6.6% decline over five years. Recent coverage of Mesoblast has focused on its position within the pharmaceuticals and biotech space and how sentiment around its...